Cargando…
A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty
BACKGROUND: Oliceridine (TRV130), a novel μ-receptor G-protein pathway selective (μ-GPS) modulator, was designed to improve the therapeutic window of conventional opioids by activating G-protein signaling while causing low β-arrestin recruitment to the μ receptor. This randomized, double-blind, pati...
Autores principales: | Singla, Neil, Minkowitz, Harold S, Soergel, David G, Burt, David A, Subach, Ruth Ann, Salamea, Monica Y, Fossler, Michael J, Skobieranda, Franck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638571/ https://www.ncbi.nlm.nih.gov/pubmed/29062240 http://dx.doi.org/10.2147/JPR.S137952 |
Ejemplares similares
-
APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty
por: Singla, Neil K., et al.
Publicado: (2019) -
APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy
por: Viscusi, Eugene R, et al.
Publicado: (2019) -
Can oliceridine (TRV130), an ideal novel µ receptor G protein pathway selective (µ-GPS) modulator, provide analgesia without opioid-related adverse reactions?
por: Ok, Hwoe Gyeong, et al.
Publicado: (2018) -
Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults
por: Lambert, David, et al.
Publicado: (2020) -
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine
por: Nafziger, Anne N., et al.
Publicado: (2019)